BIOTRONIK is releasing the Orsiro, the world’s first hybrid drug-eluting stent, in the French market. The device features a passive proBIO coating that isolates the stent’s metal from the vessel walls, and an active BIOlute biocompatible coating that releases a limus to prevent restenosis.
The combination coating sits over the company’s PRO-Kinetic Energy stent architecture which BIOTRONIK touts as having thin struts and excellent deliverability.
“We are happy to announce that the Orsiro hybrid DES, one of three stent systems in the BIOTRONIK Masterpieces portfolio along with the PRO-Kinetic Energy bare metal stent and the PK Papyrus covered stent, will now be available to yet another patient population that needs it,” Dr. Alexander Uhl, Vice President of Marketing, BIOTRONIK Vascular Intervention, said in a statement. “Physicians rely on top performing tools for each and every procedure. We see the launch of Orsiro in France as a crucial step towards giving an even greater number of physicians worldwide the chance to work with a tool that we consider a Masterpiece.”
Product page: Orsiro Hybrid Drug Eluting Stent…
Results of the BIOSCIENCE trial comparing Orsiro with Xience Prime stent in Lancet: Revisiting the BIOSCIENCE of drug-eluting stent technology…
Press release: BIOTRONIK to Offer New Treatment Options in France with Release of Orsiro Drug-Eluting Stent…
